SLC18A2

Synaptic vesicular amine transporter · Q05940 · SLC18A2 on Sugi Atlas →

13,481 patent compounds predicted against SLC18A2, 10,224 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL871273	0.59	11/20
SCHEMBL341319	0.54	11/20
SCHEMBL871092	0.66	9/20
SCHEMBL871310	0.66	9/20
SCHEMBL871649	0.65	9/20
SCHEMBL871905	0.65	9/20
Valbenazine (SCHEMBL871303)	0.65	9/20
Valbenazine (SCHEMBL871304)	0.65	9/20
Valbenazine (SCHEMBL872245)	0.65	9/20
Valbenazine (SCHEMBL872246)	0.65	9/20
SCHEMBL873306	0.62	9/20
SCHEMBL1304471	0.55	9/20
SCHEMBL1304474	0.55	9/20
SCHEMBL872223	0.66	8/20
SCHEMBL873111	0.66	8/20
Tetrabenazine (SCHEMBL62026)	1.00	7/20
Tetrabenazine (SCHEMBL340173)	1.00	7/20
Tetrabenazine (SCHEMBL1304460)	0.96	7/20
Tetrabenazine (SCHEMBL1305165)	0.92	7/20
SCHEMBL872227	0.64	7/20

Clinical trials — most relevant to SLC18A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration	PHASE4	COMPLETED
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia	PHASE1/PHASE2	RECRUITING
Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm	PHASE1/PHASE2	COMPLETED
A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder	PHASE2	WITHDRAWN
Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2	PHASE1	COMPLETED
Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1	PHASE1	COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation	EARLY_PHASE1	UNKNOWN
Mechanisms of Vasovagal Syncope	EARLY_PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI	nan	COMPLETED
Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI	nan	COMPLETED
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
DaTSCAN Brain Scintigraphy and Psychotropic Treatments: Influence on Radiotracer Binding	nan	COMPLETED
TRANSEURO Open Label Transplant Study in Parkinson's Disease	nan	COMPLETED
Stem Cell Study of Genetics and Drug Addiction	nan	COMPLETED
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting	nan	UNKNOWN
Presynaptic Imaging in Major Depressive Episodes After COVID-19	nan	RECRUITING
Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy	nan	NOT_YET_RECRUITING
Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder	nan	UNKNOWN
Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia	nan	COMPLETED
Prognostic Value of FP-CIT-SPECT in Parkinson´s Disease	nan	COMPLETED
PET Whole Body Distribution Studies Using [11C]CUMI	nan	COMPLETED
Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies	nan	COMPLETED
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)	nan	ACTIVE_NOT_RECRUITING
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED
The Effects of Dextroamphetamine on Brain Function	nan	COMPLETED
Tetrabenazine for Partial Responders	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLC18A2 binder may also engage these)

Protein	Name	Similarity
Q27963	—	1.000	Q27963 →
Q8BRU6	—	0.999	Q8BRU6 →
Q01827	—	0.989	Q01827 →
SLC18A1	Chromaffin granule amine transporter	0.984	landscape →
Q01818	—	0.980	Q01818 →
Q8R090	—	0.963	Q8R090 →
Q9WU81	—	0.954	Q9WU81 →
F1NCD6	—	0.949	F1NCD6 →
Q58CV5	—	0.949	Q58CV5 →
Q9H3U5	—	0.944	Q9H3U5 →
P57788	—	0.944	P57788 →
Q1JQC1	—	0.942	Q1JQC1 →
Q8NHS3	—	0.942	Q8NHS3 →
Q9DC37	—	0.941	Q9DC37 →
Q8TED4	—	0.941	Q8TED4 →
Q32LQ6	—	0.941	Q32LQ6 →
Q8VCV9	—	0.937	Q8VCV9 →
Q5R8G5	—	0.937	Q5R8G5 →
SPNS2	Sphingosine-1-phosphate transporter SPNS2	0.935	landscape →
SLC16A7	Monocarboxylate transporter 2	0.935	landscape →
Q7SY29	—	0.934	Q7SY29 →
Q91VM4	—	0.933	Q91VM4 →
Q5F3I6	—	0.932	Q5F3I6 →
O35910	—	0.929	O35910 →
Q5RCV1	—	0.928	Q5RCV1 →
Q5ZIT9	—	0.927	Q5ZIT9 →
P57787	—	0.927	P57787 →
Q5ZIN0	—	0.925	Q5ZIN0 →
B0JZE1	—	0.925	B0JZE1 →
Q5TF39	—	0.925	Q5TF39 →